Evidence map›Paper›PMID 37738545›Full record

ArticleJCO precision oncology2023

Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study.

Jamila Mammadova, Christelle Colin-Leitzinger, Diep Nguyen, Rahul Mhaskar, Shridar Ganesan, Yi-Han Tang, Mingxiang Teng, Roohi Ismail-Khan, Nancy Gillis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jamila MammadovaMorsani College of Medicine, University of South Florida, Tampa, FL.ORCID 0009-0008-2163-0788
Christelle Colin-LeitzingerDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.ORCID 0000-0002-8118-9591
Diep NguyenDepartment of Medical Education, Morsani College of Medicine, University of South Florida, Tampa, FL.ORCID 0000-0001-6910-261X
Rahul MhaskarDepartment of Medical Education, Morsani College of Medicine, University of South Florida, Tampa, FL.ORCID 0000-0002-3728-6052
Shridar GanesanDepartment of Medicine, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ.ORCID 0000-0002-5404-3044
Yi-Han TangDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Mingxiang TengDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Roohi Ismail-KhanDepartment of Medical Oncology, Loxo@Lilly, Indianapolis, IN.ORCID 0000-0002-1301-6736
Nancy GillisDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.ORCID 0000-0002-7744-8490
Moffitt Cancer Center · USUniversity of South Florida · USLoxo Oncology at Lilly (United States) · USRutgers, The State University of New Jersey · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironmentR01CA233662 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI GANESAN, SHRIDAR · 2019 to 2023
$3.2M
NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA233662
6 · The paper itself

Abstract

purposeThe main dose-limiting toxicity of anthracyclines is cardiotoxicity. Clonal hematopoiesis (CH), somatic mutations in hematopoietic stem or progenitor cells in patients without hematologic malignancy, is also associated with risk for adverse cardiovascular events and worse outcomes overall. We hypothesize that CH increases risk for doxorubicin-induced cardiotoxicity (DIC).

methodsWe conducted a retrospective cohort study in patients treated with doxorubicin for cancer (N = 100). Patients (n = 25) had incident symptomatic heart failure, decline in left ventricular ejection fraction, or arrhythmia. CH was identified using paired peripheral blood and tumor DNA.

resultsAfter adjusting for age at doxorubicin initiation, diabetes, dyslipidemia, and chest radiation, high cumulative dose of doxorubicin (>240 mg/m

conclusionThis study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.

Indexed as

CardiotoxicityClonal HematopoiesisDoxorubicinHumansRetrospective StudiesRisk FactorsStroke VolumeVentricular Function, LeftDoxorubicin

Identifiers

PMID37738545
PMCPMC10581654
OpenAlexW4386949985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.